Repeated Treatment with Antimalarial Agents Causes In Vitro Liver Toxicity

Crossmark: check for updates

Authors

  • David Audu Department of Pure and Applied Zoology, College of Biosciences, Federal University of Agriculture Abeokuta, Ogun State, Nigeria
  • Vinood B. Patel School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK
  • Lucy Petagine School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK
  • Olufunmilayo A. Idowu Department of Pure and Applied Zoology, College of Biosciences, Federal University of Agriculture Abeokuta, Ogun State, Nigeria
  • Adewumi B. Idowu Department of Pure and Applied Zoology, College of Biosciences, Federal University of Agriculture Abeokuta, Ogun State, Nigeria

DOI:

https://doi.org/10.17140/lroj-4-113

Keywords:

Cell death, Reactive oxygen species, Artesunate, Amodiaquine, Artemether, Lumefantrine, Malaria

Abstract

Aim
In Africa’s malaria-endemic regions, artesunate/amodiaquine (A/A) and artemether/lumefantrine (A/L) are the antimalarial medications that are most frequently prescribed. Antimalarial medications could be overused if they are self-prescribed based on symptoms rather than a parasitological diagnosis. This investigation looked at potential cytotoxic and oxidative stress effects following three dosage treatments spaced 24 h apart.
Method
Artesunate (50 μM and 100 μM), Amodiaquine (1 μM and 10 μM), Artemether (200 μM and 400 μM), and Lumefantrine (200 μM and 400 μM) were administered to HepG2-derived VL-17A for up to 72 h.
Result
With a downward trend from 24 h to 48 h to 72 h, the study findings showed that repeated administration of these medications greatly reduced cell viability. Additionally, for artemether 200 μM treatment, the reactive oxygen species (ROS) levels increased after 24 h and 48 h but considerably decreased after 72 h. The ROS levels in artesunate, amodiaquine, artemether 400 μM, and lumefantrine were also noticeably lower after 72 h.
Conclusion
The results of this experiment show that repeated applications of anti-malaria drugs, A/L and A/A to HepG2 liver cells reduced their viability in a manner that was consistent. These findings have significant implications for those who use antimalarial medications as a preventative measure without a diagnosis of parasite infection.

References

Audu D, Petagine L, Idowu OA, Patel VB, Idowu AB. Biomark-ers of the toxic effects of chemotherapeutic agents: A focus on antimalarials. In: Patel VB, Preedy VR, Rajendram R, eds. Bio-markers in Toxicology. Biomarkers in Disease: Methods, Discoveries and Brief Research Report | Volume 4 | Number 1| Audu D, et al Applications. NY, USA: Springer, Cham; 2023. doi: 10.1007/978- 3-030-87225-0_73-2

World Health Organization (WHO). World malaria report 2022. Web site. https://www.who.int/teams/global-malaria-pro-gramme/reports/world-malaria-report-2022. Accessed Novem-ber 12, 2022.

Wangdi K, Furuya-Kanamori L, Clark J, et al. Comparative ef-fectiveness of malaria prevention measures: A systematic review and network meta-analysis. Parasit Vectors. 2018; 11(1): 210. doi: 10.1186/s13071-018-2783-y

Aminake NM, Pradel G. Antimalarial drugs resistance in Plas-modium falciparum and the current strategies to overcome them. Microbial Pathogens and Strategies for Combating them: Science, Technology and Education. 2013; 1: 269-282.

Koko VS, Warsame M, Vonhm B, et al. Artesunate–amo-diaquine and artemether–lumefantrine for the treatment of un-complicated falciparum malaria in Liberia: In vivo efficacy and frequency of molecular markers. Malar. J. 2022; 21: 134. doi: 10.1186/s12936-022-04140-7

Kavishe RA, Koenderink JB, Alifrangis M. Oxidative stress in malaria and artemisinin combination therapy: Pros and cons. FEBS Journal. 2017; 284: 2579-2591. doi: 10.1111/febs.14097

Olliaro PL, Haynes RK, Meunier B, Yuthavong Y. Possible modes of action of the artemisinin-type compounds. Trends Para-sitol. 2001; 17: 122-126. doi: 10.1016/S1471-4922(00)01838-9

Egwu CO, Augereau JM, Reybier K, Benoit-Vical F. Reactive oxygen species as the brainbox in malaria treatment. Antioxidants. 2021; 10: 1872. doi: 10.3390/antiox10121872

Owumi SE, Gbadegesin MA, Odunola OA, Adegoke AM, Uwaifo AO. Toxicity associated with repeated administration of artemether-lumefantrine in rats. Environ Toxicol. 2015; 30: 301- 307. doi: 10.1002/tox.21907

Taylor WRJ, White NJ. Antimalarial drug toxicity: A review. Drug Saf. 2004; 27: 25-61. doi: 10.2165/00002018-200427010-

Idowu ET, Alimba CG, Olowu EA, Otubanjo AO. Arte-mether-Lumefantrine treatment combined with albendazole and ivermectin induced genotoxicity and hepatotoxicity through oxi-dative stress in Wistar rats. Egypt J Basic Appl Sci. 2015; 2: 110-119. doi: 10.1016/j.ejbas.2015.03.001

Yin S, Yang H, Zhao X, et al. Antimalarial agent artesunate induces G0/G1 cell cycle arrest and apoptosis via increasing in-tracellular ROS levels in normal liver cells. Hum Exp Toxicol. 2020; 39: 1681-1689. doi: 10.1177/0960327120937331

Ghazali R, Mehta KJ, Bligh SA, Tewfik I, Clemens D, Patel VB. High omega arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered lipid metabolism in human hepatoma cells. World J Hepatol. 2020; 12: 84-98. doi: 10.4254/wjh.v12.i3.84

Eruslanov E, Kusmartsev S. Identification of ROS using oxi-dized DCFDA and flow-cytometry. Methods Mol Biol. 2010; 594: 57-72. doi: 10.1007/978-1-60761-411-1_4

Silva-Pinto A, Ruas R, Almeida F, et al. Artemether-lumefan-trine and liver enzyme abnormalities in non-severe Plasmodium falciparum malaria in returned travellers: A retrospective com-parative study with quinine-doxycycline in a Portuguese centre. Malar J. 2017; 16: 1-5. doi: 10.1186/s12936-017-1698-y

Adaramoye OA, Osaimoje DO, Akinsanya AM, Nneji CM, Fafunso MA, Ademowo OG. Changes in antioxidant status and biochemical indices after acute administration of artemether, artemether-lumefantrine and halofantrine in rats. Basic Clin. Pharmacol. Toxicol. 2008; 102: 412-418. doi: 10.1111/j.1742- 7843.2008.00211.x Submit your article to this journal | https://openventio.org/submit-manuscript/

Efferth T, Glaisi M, Merling A, Krammer PH, Li-Weber M. Artesunate induces ROS-mediated apoptosis in Doxorubicin-resistant T leukemia cells. PLoS One. 2007; 2: e693. doi: 10.1371/ journal.pone.0000693

Kerb R, Fux R, Mörike K, et al. Pharmacogenetics of antima-larial drugs: effect on metabolism and transport. Lancet Infect Dis. 2009; 9: 760-774. doi: 10.1016/S1473-3099(09)70320-2

Deavall DG, Martin EA, Horner JM, Roberts R. Drug-in-duced oxidative stress and toxicity. J Toxicol. 2012; 2012: 645460. doi: 10.1155/2012/645460

Alkadi HO. Antimalarial drug toxicity: A review. Chemotherapy. 2007; 53: 385-391. doi: 10.1159/000109767

Adisa R, Fakeye T, Dike D. Evaluation of adverse drug reac-tions to artemisinin-based combination therapy in a Nigeria Uni-versity Community. Tropical Journal of Pharmaceutical Research. 2008; 7: 937. doi: 10.4314/tjpr.v7i2.14680

Downloads

Published

2023-01-10

How to Cite

David Audu, Vinood B. Patel, Lucy Petagine, Olufunmilayo A. Idowu, & Adewumi B. Idowu. (2023). Repeated Treatment with Antimalarial Agents Causes In Vitro Liver Toxicity. Liver Research, 4(1), 1–6. https://doi.org/10.17140/lroj-4-113

Issue

Vol. 4 No. 1 (2023): Volume 4 Issue 1 2023

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Liver Research (LROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.